Commons Health Select Committee ‘Brexit – Medicines, medical devices and substances of human origin’ inquiry – first session held
The first oral evidence session of the House of Commons Health Select Committee inquiry on ‘Brexit – Medicines, medical devices and substances of human origin’ was held on Tuesday 5 December 2017.
In the first session, witnesses from the distribution and supply chain aspects of medicines discussed the impact of Brexit. Transparency and the need for a political settlement and a two-year transition period were discussed as being key to limiting the impact on patients. Evidence in this session was heard from the following witnesses:
- Martin Sawer, executive director of the Healthcare Distribution Association;
- Dr Jeanette Dickson, vice president of the Faculty of Clinical Oncology, Royal College of Radiologists;
- Dr Andrew Grainger, assistant professor in logistics and supply chain management, University of Nottingham;
- Richard Freudenberg, secretary-general of the British Association of European Pharmaceutical Distributors;
The second session focused on substances of human origin where the issue of regulatory divergence and patient safety was discussed by the following witnesses:
- Ian Bateman, director of quality at NHS Blood and Transplant;
- Fiona Loud, policy director, Kidney Care UK;
- Liz Carroll, chief executive, The Haemophilia Society;
- Professor Jean McHale, professor of healthcare law and director of the Centre for Health Law, Science and Policy, University of Birmingham.
The next evidence session will be held on Tuesday 12 December 2017.